Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of Pembrolizumab Plus 177Lu-PSMA-617 in Patients With Metastatic Castration Resistant Prostate Cancer

NCT05766371 is registered in ClinicalTrials.gov with University of California, San Francisco as lead sponsor.

NCT NCT05766371
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05766371 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of Pembrolizumab Plus 177Lu-PSMA-617 in Patients With Metastatic Castration Resistant Prostate Cancer
Lead sponsor
University of California, San Francisco
Phase
Phase 2
Overall status
Recruiting
Start date
December 15, 2023
Completion date
May 31, 2031
Enrollment
48 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

castrate resistant prostate cancer, metastatic castration-resistant prostate cancer, prostate cancer, prostate carcinoma